MedTrace Logo

Safety Study of MM-121 in Combination With Multiple Anticancer Therapies in Patients With Advanced Solid Tumors

NCT01447225 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2016-09-14

Study results available
· View outcomes & findings →

Summary

To evaluate the safety and tolerability of escalating doses of MM-121 + certain anticancer therapies

Conditions

Interventions

DRUG

MM-121

MM-121 administered at 20 mg/kg IV loading dose followed by12mg/kg/week IV or 40 mg/kg IV loading dose followed by 20mg/kg/week IV

DRUG

Carboplatin

administered at AUC 6

DRUG

Pemetrexed

administered IV at 500 mg/m2

DRUG

Cabazitaxel

administered IV at 20 mg/m2 or 25 mg/m2

DRUG

Gemcitabine

administered IV at 1000 mg/m2 or 1250 mg/m2

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • Merrimack Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Victor Moyo, MD · Merrimack Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-10-31
Primary Completion
2013-11-30
Completion
2014-01-31

Countries

  • United States
  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01447225 on ClinicalTrials.gov